Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

NCT00671970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
Gliosarcoma

Interventions

DRUG: Bevacizumab and Erlotinib

Sponsor

Duke University

Collaborators

[object Object]